


a bone or cartilage fracture.

for a time + under conditions frequently cartilage and bone
REMARKS

Reconsideration of this application is requested in view of the amendments to the claims and the remarks presented herein.

The claims in the application are claims 2 to 5, 8 to 11, 14 and 15, all other claims having been cancelled. It should be noted that claim 15 drawn to the method uses the composition of claim 14 which is drawn to a collagen-free aqueous solution of a polyoxyethylene-polyoxypropylene glycol and an effective amount of a bone morphogenetic protein. Claim 13 has been cancelled and is no longer subject to the rejections thereto. With respect to the Examiner's allegation that claims 10 and 11 are duplicate of one another, this is incorrect since claim 10 is directed to the use of the bone morphogenetic protein BMP-2 and claim 11 is drawn to the use of the bone morphogenetic protein MP-52. Therefore, these are not duplicates of each other. Claim 15 has been amended as suggested by the Examiner with respect to the warm-blooded animal.

On page 4 of the office action, the Examiner held that the application failed to comply with the requirements as set forth in the notice to comply with the amino sequence disclosure because "Upon compliance with the requirements, Applicant must also amend the application to provide the SEQ ID Nos in the specification at



What is claimed is:

RECEIVED
SEP 18 2001
TECH CENTER 1600/2900

1. A cartilage and bone morphogenetic repairing material which comprises ^{aqueous solution of} a polyoxyethylene-polyoxypropylene glycol and a bone morphogenetic protein.
2. The cartilage and bone morphogenetic repairing material as claimed in claim ¹⁴ 1, wherein the polypropylene glycol as a constituent of said polyoxyethylene-polyoxypropylene glycol has a molecular weight of about 1,500-4,000 and ^{the} an ethylene oxide content of about 40-80% ^{per} molecule.
3. The cartilage and bone morphogenetic repairing material as claimed in claim 2, wherein a concentration of said polyoxyethylene-polyoxypropylene glycol in an aqueous solution is about 10-50%.
4. The cartilage and bone morphogenetic repairing material as claimed in either one of claims 1-3, wherein said bone morphogenetic protein is BMP-2.
5. The cartilage and bone morphogenetic repairing material as claimed in either one of claims 1-3, wherein said bone morphogenetic protein is MP52. *SEQ ID ?*
6. A cartilage and bone repairing agent comprising a polyoxyethylene-polyoxypropylene glycol and a bone morphogenetic protein.
7. A method of treatment for a cartilage and bone repairing, whereby a cartilage and bone morphogenetic agent comprising a polyoxyethylene-polyoxypropylene glycol in combination with a bone morphogenetic protein is administered locally to the site of bone fracture or bone defect of human or animal.